CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial

MeSH terms

• Cardiovascular Diseases* / diagnosis
• Cardiovascular Diseases* / etiology
• Cardiovascular Diseases* / mortality
• Cardiovascular Diseases* / surgery
• Clopidogrel* / administration & dosage
• Clopidogrel* / adverse effects
• Clopidogrel* / pharmacokinetics
• Cytochrome P-450 CYP2C19 / genetics*
• Extremities / blood supply
• Female
• Hemorrhage* / chemically induced
• Hemorrhage* / diagnosis
• Humans
• Ischemia* / etiology
• Ischemia* / surgery
• Loss of Function Mutation
• Male
• Middle Aged
• Outcome and Process Assessment, Health Care
• Peripheral Arterial Disease* / complications
• Peripheral Arterial Disease* / drug therapy
• Peripheral Arterial Disease* / genetics
• Pharmacogenomic Testing / methods
• Platelet Aggregation Inhibitors / administration & dosage
• Platelet Aggregation Inhibitors / adverse effects
• Platelet Aggregation Inhibitors / pharmacokinetics
• Vascular Surgical Procedures* / methods
• Vascular Surgical Procedures* / statistics & numerical data